Potential therapeutic radiotracers: Preparation, biodistribution and metabolic characteristics of 177Lu-labeled cyclic RGDfK dimer

Amino Acids

Volumn 39, Issue 1, 2010, Pages 111-120

  Shi, Jiyun ^a   Liu, Zhaofei ^a   Jia, Bing ^a   Yu, Zilin ^a   Zhao, Huiyun ^a   Wang, Fan ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

177Lu; DTPA Bz; Integrin v 3; RGD; Tumor therapy

Indexed keywords

CHELATING AGENT; CYCLO(ARGINYLGLYCYLASPARTYLPHENYLALANYLLYSINE) 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LU 177; CYCLO(ARGINYLGLYCYLASPARTYLPHENYLALANYLLYSINE) 2 (4 ISOTHIOCYANOBENZYL) 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LU 177; CYCLO(ARGINYLGLYCYLASPARTYLPHENYLALANYLLYSINE) 2 (4 ISOTHIOCYANOBENZYL)PENTETIC ACID LU 177; CYCLOPEPTIDE; LUTETIUM 177; TRACER; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG SOLUBILITY; DRUG STRUCTURE; GLIOMA; HEATING; HUMAN; HUMAN TISSUE; ISOTOPE LABELING; LIPOPHILICITY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; ROOM TEMPERATURE; TREATMENT RESPONSE;

ANIMALS; DIMERIZATION; HUMANS; INTEGRIN ALPHAVBETA3; KINETICS; LUTETIUM; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR CONFORMATION; ORGANOPHOSPHORUS COMPOUNDS; PEPTIDES, CYCLIC; RADIOISOTOPES; TIME FACTORS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 77953620395     PISSN: 09394451     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00726-009-0382-0     Document Type: Article

References (37)

1. A Abdollahi DW Griggs H Zieher A Roth KE Lipson R Saffrich H-J Gröne DE Hallahan RA Reisfeld J Debus, et al. 2005 Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy Clin Cancer Res 11 17 6270 6279 10.1158/1078-0432.CCR-04-1223 1:CAS:528:DC%2BD2MXpslansLs%3D 16144931 (Pubitemid 41262958)
2. GC Alghisi C Rüegg 2006 Vascular integrins in tumor angiogenesis: mediators and therapeutic targets Endothelium 13 2 113 135 10.1080/ 10623320600698037 1:CAS:528:DC%2BD28XmvV2jt7w%3D 16728329 (Pubitemid 44173112)
3. AJ Beer R Haubner M Sarbia M Goebel S Luderschmidt AL Grosu O Schnell M Niemeyer H Kessler HJ Wester, et al. 2006 Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man Clin Cancer Res 12 13 3942 3949 10.1158/1078-0432.CCR-06-0266 1:CAS:528:DC%2BD28XmsValtLk%3D 16818691 (Pubitemid 44078079)
4. AJ Beer AL Grosu J Carlsen A Kolk M Sarbia I Stangier P Watzlowik HJ Wester R Haubner M Schwaiger 2007 [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck Clin Cancer Res 13 22 Pt 1 6610 6616 10.1158/1078-0432.CCR-07-0528 1:CAS:528:DC%2BD2sXhtlSmu7nO 18006761 (Pubitemid 350206795)
5. PJ Blower JS Lewis J Zweit 1996 Copper radionuclides and radiopharmaceuticals in nuclear medicine Nucl Med Biol 23 8 957 980 10.1016/S0969-8051(96)00130-8 1:CAS:528:DyaK2sXkslOqsQ%3D%3D 9004284 (Pubitemid 27050682)
6. PC Brooks RA Clark DA Cheresh 1994 Requirement of vascular integrin alpha v beta 3 for angiogenesis Science 264 5158 569 10.1126/science.7512751 1:CAS:528:DyaK2cXjt1Sis7w%3D 7512751
7. W Cai G Niu X Chen 2008 Imaging of integrins as biomarkers for tumor angiogenesis Curr Pharm Des 14 28 2943 2973 10.2174/138161208786404308 1:CAS:528:DC%2BD1MXmt1ehsQ%3D%3D 18991712
8. X Chen S Liu Y Hou M Tohme R Park JR Bading PS Conti 2004 MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides Mol Imaging Biol 6 5 350 359 10.1016/j.mibio.2004.06.004 15380745 (Pubitemid 39243068)
9. M De Jong WH Bakker EP Krenning WA Breeman ME van der Pluijm BF Bernard TJ Visser E Jermann M Behe P Powell, et al. 1997 Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0, d-Phe1, Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy Eur J Nucl Med 24 4 368 371 10.1007/BF00881807 9096086
10. B de Keizer MO van Aken RA Feelders WW de Herder BL Kam M van Essen EP Krenning DJ Kwekkeboom 2008 Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0, Tyr3]octreotate Eur J Nucl Med Mol Imaging 35 4 749 755 10.1007/s00259-007-0691- z 1:CAS:528:DC%2BD1cXjsVClu7s%3D 18210106
11. SV Deshpande SJ DeNardo DL Kukis MK Moi MJ McCall GL DeNardo CF Meares 1990 Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent J Nucl Med 31 4 473 479 1:CAS:528:DyaK3cXksleru74%3D 2324823
12. J Folkman 2003 Fundamental concepts of the angiogenic process Curr Mol Med 3 7 643 651 10.2174/1566524033479465 1:CAS:528:DC%2BD3sXotFOjsrg%3D 14601638 (Pubitemid 37236406)
13. RH Haubner HJ Wester WA Weber M Schwaiger 2003 Radiotracer-based strategies to image angiogenesis Q J Nucl Med 47 3 189 199 1:STN:280: DC%2BD3szmsVaisQ%3D%3D 12897710
14. B Jia J Shi Z Yang B Xu Z Liu H Zhao S Liu F Wang 2006 99mTc-labeled cyclic RGDfK dimer: initial evaluation for SPECT imaging of glioma integrin alphavbeta3 expression Bioconjug Chem 17 4 1069 1076 10.1021/bc060055b 1:CAS:528:DC%2BD28Xmt1Khsrg%3D 16848417 (Pubitemid 44162628)
15. B Jia Z Liu J Shi Z Yu Z Yang H Zhao Z He S Liu F Wang 2008 Linker effects on biological properties of 111In-labeled DTPA conjugates of a cyclic RGDfK dimer Bioconjug Chem 19 1 201 210 10.1021/bc7002988 1:CAS:528: DC%2BD2sXhsVWqsLnM 18069778 (Pubitemid 351213852)
16. H Jin J Varner 2004 Integrins: roles in cancer development and as treatment targets Br J Cancer 90 3 561 565 10.1038/sj.bjc.6601576 1:CAS:528:DC%2BD2cXoslKjug%3D%3D 14760364 (Pubitemid 38297190)
17. LM Kenny RC Coombes I Oulie KB Contractor M Miller TJ Spinks B McParland PS Cohen AM Hui C Palmieri, et al. 2008 Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients J Nucl Med 49 6 879 886 10.2967/jnumed.107.049452 18483090 (Pubitemid 351793427)
18. S Liu 2004 The role of coordination chemistry in the development of target-specific radiopharmaceuticals Chem Soc Rev 33 7 445 461 10.1039/b309961j 1:CAS:528:DC%2BD2cXntlWmtb8%3D 15354226 (Pubitemid 39461952)
19. S Liu 2006 Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging Mol Pharm 3 5 472 487 10.1021/mp060049x 1:CAS:528:DC%2BD28XntVKgtr8%3D 17009846 (Pubitemid 44639125)
20. S Liu DS Edwards 2001 Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals Bioconjug Chem 12 1 7 34 10.1021/bc000070v 11170362 (Pubitemid 32113652)
21. S Liu DS Edwards 2001 Synthesis and characterization of two (111)In-labeled DTPA-peptide conjugates Bioconjug Chem 12 4 630 634 10.1021/bc010013h 1:CAS:528:DC%2BD3MXkt1ersrs%3D 11459469 (Pubitemid 32696238)
22. S Liu E Cheung M Rajopadhye NE Williams KL Overoye DS Edwards 2001 Isomerism and solution dynamics of (90)Y-labeled DTPA-biomolecule conjugates Bioconjug Chem 12 1 84 91 10.1021/bc000071n 1:CAS:528:DC%2BD3cXovFalu70%3D 11170370 (Pubitemid 32113653)
23. S Liu E Cheung MC Ziegler M Rajopadhye DS Edwards 2001 (90)Y and (177)Lu labeling of a DOTA-conjugated vitronectin receptor antagonist useful for tumor therapy Bioconjug Chem 12 4 559 568 10.1021/bc000146n 1:CAS:528: DC%2BD3MXkt1Wktr8%3D 11459461 (Pubitemid 32696230)
24. Z Liu F Wang X Chen 2008 Integrin alpha v beta 3-targeted cancer therapy Drug Dev Res 69 6 329 339 10.1002/ddr.20265 1:CAS:528:DC%2BD1MXhtl2hug%3D%3D
25. Z Liu Z Li Q Cao S Liu F Wang X Chen 2009 Small-animal PET of tumors with 64Cu-labeled RGD-bombesin heterodimer J Nucl Med 50 7 1168 1177 10.2967/jnumed.108.061739 1:CAS:528:DC%2BD1MXpsV2gsbY%3D 19525469
26. Z Liu S Liu F Wang S Liu X Chen 2009 Noninvasive imaging of tumor integrin expression using (18)F-labeled RGD dimer peptide with PEG (4) linkers Eur J Nucl Med Mol Imaging 36 8 1296 1307 10.1007/s00259-009-1112-2 1:CAS:528:DC%2BD1MXotl2nur8%3D 19296102
27. Z Liu G Niu J Shi S Liu F Wang S Liu X Chen 2009 (68)Ga-labeled cyclic RGD dimers with Gly(3) and PEG (4) linkers: promising agents for tumor integrin alpha (v)beta (3) PET imaging Eur J Nucl Med Mol Imaging 36 6 947 957 10.1007/s00259-008-1045-1 1:CAS:528:DC%2BD1MXls1yjsL0%3D 19159928
28. Z Liu Y Yan FT Chin F Wang X Chen 2009 Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using 18F-labeled PEGylated RGD-bombesin heterodimer 18F-FB-PEG3-Glu-RGD-BBN J Med Chem 52 2 425 432 10.1021/jm801285t 1:CAS:528:DC%2BD1MXnt1Kg 19113865
29. MK Moi CF Meares MJ McCall WC Cole SJ DeNardo 1985 Copper chelates as probes of biological systems: stable copper complexes with a macrocyclic bifunctional chelating agent Anal Biochem 148 1 249 253 10.1016/0003-2697(85) 90653-0 1:CAS:528:DyaL2MXltlyjsLs%3D 4037304 (Pubitemid 15031793)
30. JJ Peterson CF Meares 1999 Enzymatic cleavage of peptide-linked radiolabels from immunoconjugates Bioconjug Chem 10 4 553 557 10.1021/bc990010t 1:CAS:528:DyaK1MXjtFegs70%3D 10411450 (Pubitemid 29355231)
31. J Shi L Wang YS Kim S Zhai Z Liu X Chen S Liu 2008 Improving tumor uptake and excretion kinetics of 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers J Med Chem 51 24 7980 7990 10.1021/jm801134k 1:CAS:528:DC%2BD1cXhsVKlu73K 19049428
32. J Shi YS Kim S Zhai Z Liu X Chen S Liu 2009 Improving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkers Bioconjug Chem 20 4 750 759 10.1021/bc800455p 1:CAS:528:DC%2BD1MXjs1Gksb4%3D 19320477
33. JB Stimmel FC Kull Jr 1998 Samarium-153 and lutetium-177 chelation properties of selected macrocyclic and acyclic ligands Nucl Med Biol 25 2 117 125 10.1016/S0969-8051(97)00151-0 1:CAS:528:DyaK1cXmt1yntg%3D%3D 9468026 (Pubitemid 28032164)
34. JB Stimmel ME Stockstill FC Kull Jr 1995 Yttrium-90 chelation properties of tetraazatetraacetic acid macrocycles, diethylenetriaminepentaacetic acid analogues, and a novel terpyridine acyclic chelator Bioconjug Chem 6 2 219 225 10.1021/bc00032a010 1:CAS:528:DyaK2MXktlertL0%3D 7599265
35. K Temming RM Schiffelers G Molema RJ Kok 2005 RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature Drug Resist Updat 8 6 381 402 10.1016/j.drup.2005.10.002 1:CAS:528: DC%2BD28Xit1Crsr4%3D 16309948 (Pubitemid 43358061)
36. A Veeravagu Z Liu G Niu K Chen B Jia W Cai C Jin AR Hsu AJ Connolly V Tse, et al. 2008 Integrin alphavbeta3-targeted radioimmunotherapy of glioblastoma multiforme Clin Cancer Res 14 22 7330 7339 10.1158/1078-0432.CCR- 08-0797 1:CAS:528:DC%2BD1cXhtlylur%2FM 19010848
37. L Wang J Shi YS Kim S Zhai B Jia H Zhao Z Liu F Wang X Chen S Liu 2009 Improving tumor-targeting capability and pharmacokinetics of (99m)Tc-labeled cyclic RGD dimers with PEG(4) linkers Mol Pharm 6 1 231 245 10.1021/mp800150r 1:CAS:528:DC%2BD1cXhsVOmt77I 19067525